BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan flag Japan · Delayed Price · Currency is JPY
82.00
+30.00 (57.69%)
Jul 4, 2025, 3:30 PM JST

TYO:4594 Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025 FY 2024 FY 2018 FY 2017
Period Ending
Mar '25 Mar '24 Mar '18 Mar '17
1.130.07354529
Revenue Growth (YoY)
1473.61%-99.98%-33.08%-
Cost of Revenue
0.030.02316525
Gross Profit
1.10.05384
Selling, General & Admin
1,1621,155344299
Research & Development
--1,253816
Operating Expenses
1,1621,1551,6001,118
Operating Income
-1,161-1,155-1,562-1,114
Interest & Investment Income
0.070.01--
Currency Exchange Gain (Loss)
2.25-2.66--1
Other Non Operating Income (Expenses)
-4.38-1.2-11-1
EBT Excluding Unusual Items
-1,163-1,159-1,573-1,116
Asset Writedown
-1.37-7.25--
Other Unusual Items
15.11---
Pretax Income
-1,149-1,166-1,573-1,116
Income Tax Expense
1.91.955
Earnings From Continuing Operations
-1,151-1,168-1,578-1,121
Minority Interest in Earnings
--18
Net Income
-1,151-1,168-1,577-1,113
Net Income to Common
-1,151-1,168-1,577-1,113
Shares Outstanding (Basic)
82643834
Shares Outstanding (Diluted)
82643834
Shares Change (YoY)
27.03%67.81%12.41%-
EPS (Basic)
-14.12-18.21-41.25-32.72
EPS (Diluted)
-14.12-18.21-41.25-32.72
Free Cash Flow
-1,252-1,163-1,699-1,164
Free Cash Flow Per Share
-15.36-18.13-44.44-34.22
Gross Margin
97.18%75.00%10.73%0.76%
Operating Margin
-102464.08%-1604276.39%-441.24%-210.59%
Profit Margin
-101601.85%-1622336.11%-445.48%-210.40%
Free Cash Flow Margin
-110479.17%-1615436.11%-479.94%-220.04%
EBITDA
--1,155-1,489-1,073
EBITDA Margin
----202.84%
D&A For EBITDA
-0.47341
EBIT
-1,161-1,155-1,562-1,114
EBIT Margin
----210.59%
Updated Feb 14, 2019. Source: S&P Global Market Intelligence. Standard template. Financial Sources.